-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the continuous improvement of local pharmaceutical companies in the research and development of new drugs, the license out of new drugs has become more and more frequent
.
Since the beginning of this year, many companies have successfully launched innovative drugs overseas
.
For example, Luye Pharma announced some time ago that it has entered into cooperation with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis), granting Exeltis the exclusive commercialization rights of Mindoril transdermal patch in Mexico and Poland
.
It is reported that the Ristigmine multi-day transdermal patch is a new twice-weekly patch dosage form for the treatment of mild to moderate dementia associated with Alzheimer's disease
.
The product was developed by Luye Pharma's proprietary transdermal drug delivery technology platform and has obtained marketing approvals in several European countries
.
In addition, Boaoxin also recently announced that it has reached a cooperation with Pyxis Oncology, granting Pyxis Oncology the exclusive license rights for the global development and commercialization of anti-Siglec-15 monoclonal antibody BSI-060T except for Greater China
.
Under the agreement, Boosin will receive an upfront payment of $10 million, milestone payments totaling up to $222 million and royalties up to a double-digit percentage of sales
.
It is reported that BSI-060T is an anti-Siglec-15 monoclonal antibody.
Preclinical studies have shown that BSI-060T has higher affinity, stronger biological activity, and longer half-life than the benchmark drug
.
It is worth noting that, through the published information, it can be clearly found that Boosin has reached a number of global development cooperation for innovative drugs in just a few years
.
Specifically, in addition to the BSI-060T drug pipeline, the company has successfully reached global cooperative development with a number of listed pharmaceutical companies at home and abroad for 7 drug pipelines including BSI-045B and BSI-04702 in the past two years.
transaction, granting it an exclusive license to develop and commercialize some of its territories
.
The frequent realization of global license outs undoubtedly demonstrates the strong R&D strength of Boosin
.
There is still a big gap between the license out transaction situation of the innovation capability of domestic new drugs and the license in of the introduction of international pipelines.
This is very eye-catching under the background that domestic innovative drugs are still in the active exploration stage in terms of global cooperation
.
It is understood that, in fact, "license out" has become a very important criterion for pharmaceutical companies in terms of their international innovation and R&D capabilities
.
However, according to data, from 2017 to 2019, the number of domestic innovative drugs that went overseas in the form of license out in cross-border transaction cooperation did not exceed 10 models
.
From 2020 to 2021, the number of license out transactions will increase rapidly, and it has not yet exceeded the 50 model mark
.
Among them, there are only 6 transactions that have reached license out in the preclinical stage, accounting for only 15% of all transactions
.
Therefore, on the whole, domestic innovative drugs are still in the active exploration stage in terms of global cooperation
.
In this context, how should domestic innovative pharmaceutical companies solve the problem of "going overseas" and accelerate the pace of internationalization of domestic new drugs? Industry analysts believe that this should break through from three aspects: first, to conduct differentiated R&D projects and innovative discovery for the global drug landscape; second, when conducting global preclinical and international multi-center clinical trials, pharmaceutical companies must Standards, trial quality control, international registration, etc.
must be very familiar; third, in the market expansion of international business, maintain close cooperation and exchanges with multinational pharmaceutical companies and international scientific research institutions
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Since the beginning of this year, many companies have successfully launched innovative drugs overseas
.
For example, Luye Pharma announced some time ago that it has entered into cooperation with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis), granting Exeltis the exclusive commercialization rights of Mindoril transdermal patch in Mexico and Poland
.
It is reported that the Ristigmine multi-day transdermal patch is a new twice-weekly patch dosage form for the treatment of mild to moderate dementia associated with Alzheimer's disease
.
The product was developed by Luye Pharma's proprietary transdermal drug delivery technology platform and has obtained marketing approvals in several European countries
.
In addition, Boaoxin also recently announced that it has reached a cooperation with Pyxis Oncology, granting Pyxis Oncology the exclusive license rights for the global development and commercialization of anti-Siglec-15 monoclonal antibody BSI-060T except for Greater China
.
Under the agreement, Boosin will receive an upfront payment of $10 million, milestone payments totaling up to $222 million and royalties up to a double-digit percentage of sales
.
It is reported that BSI-060T is an anti-Siglec-15 monoclonal antibody.
Preclinical studies have shown that BSI-060T has higher affinity, stronger biological activity, and longer half-life than the benchmark drug
.
It is worth noting that, through the published information, it can be clearly found that Boosin has reached a number of global development cooperation for innovative drugs in just a few years
.
Specifically, in addition to the BSI-060T drug pipeline, the company has successfully reached global cooperative development with a number of listed pharmaceutical companies at home and abroad for 7 drug pipelines including BSI-045B and BSI-04702 in the past two years.
transaction, granting it an exclusive license to develop and commercialize some of its territories
.
The frequent realization of global license outs undoubtedly demonstrates the strong R&D strength of Boosin
.
There is still a big gap between the license out transaction situation of the innovation capability of domestic new drugs and the license in of the introduction of international pipelines.
This is very eye-catching under the background that domestic innovative drugs are still in the active exploration stage in terms of global cooperation
.
It is understood that, in fact, "license out" has become a very important criterion for pharmaceutical companies in terms of their international innovation and R&D capabilities
.
However, according to data, from 2017 to 2019, the number of domestic innovative drugs that went overseas in the form of license out in cross-border transaction cooperation did not exceed 10 models
.
From 2020 to 2021, the number of license out transactions will increase rapidly, and it has not yet exceeded the 50 model mark
.
Among them, there are only 6 transactions that have reached license out in the preclinical stage, accounting for only 15% of all transactions
.
Therefore, on the whole, domestic innovative drugs are still in the active exploration stage in terms of global cooperation
.
In this context, how should domestic innovative pharmaceutical companies solve the problem of "going overseas" and accelerate the pace of internationalization of domestic new drugs? Industry analysts believe that this should break through from three aspects: first, to conduct differentiated R&D projects and innovative discovery for the global drug landscape; second, when conducting global preclinical and international multi-center clinical trials, pharmaceutical companies must Standards, trial quality control, international registration, etc.
must be very familiar; third, in the market expansion of international business, maintain close cooperation and exchanges with multinational pharmaceutical companies and international scientific research institutions
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
